Previous 10 | Next 10 |
BOSTON, March 28, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that the Company will present at the H.C Wainwright Global Life ...
BOSTON, March 18, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that Douglas Pagán, Chief Financial Officer, has resigned, ...
In October 2018, Paratek Pharmaceuticals ( PRTK ) received FDA approvals for its two main products - SEYSARA and NUZYRA. The company also entered into an exclusive licensing agreement with Almirall ( LBTSF ) for the development and commercialization rights of SEYSARA, which was launched in the...
BOSTON, March 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that the Company will present at the Cowen and Company 39 th An...
The following slide deck was published by Paratek Pharmaceuticals, Inc. in conjunction with their 2018 Q4 earnings Read more ...
Paratek Pharmaceuticals, Inc. (PRTK) Q4 2018 Earnings Conference Call February 27, 2019 16:30 ET Corporate Participants Ben Strain - Executive Director Investor Relations and Corporate Communications Michael Bigham - Chairman and Chief Executive Officer Adam Woodrow - Chief Comme...
Paratek Pharmaceuticals (NASDAQ: PRTK ): Q4 GAAP EPS of -$0.71 misses by $0.02 . Revenue of $17M (+235.3% Y/Y) in-line. Press Release More news on: Paratek Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
-- NUZYRA™ (omadacycline) Launched in the United States for the Treatment of CABP and ABSSSI -- -- New England Journal of Medicine Publishes Results from Two Pivotal Phase 3 Studies of NUZYRA -- -- Company Executes SEYSARA™ Royalty-Backed Loan to Receive $32.5 M...
This article is part of a series that provides an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 02/13/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for ...
BOSTON, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK ), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced the Company will host a conference call and live audio webcast ...
News, Short Squeeze, Breakout and More Instantly...
Paratek Pharmaceuticals Inc. Company Name:
PRTK Stock Symbol:
NASDAQ Market:
Paratek Pharmaceuticals Inc. Website:
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Paratek Pharmaceuticals Inc. (PRTK) is expected to report $-0.25 for Q3 2023
BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military ...